Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer

por Poon, Darren M.C., Ng, Joyce, Chan, Kuen
Publicado 2015

Real-world experience of cabozantinib in Asian patients with advanced renal cell carcinoma following treatment with VEGFR tyrosine kinase inhibitors and/or immune-checkpoint inhibi...

por Poon, Darren MC, Chan, Kuen, Leung, Angus Kwong-Chuen, Ng, Brian, Cheung, Foon-Yiu, Siu, Steven Wai-Kwan
Publicado 2023

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience

por Poon, Darren M. C., Chan, Kuen, Lee, S. H., Chan, T. W., Sze, Henry, Lee, Eric K. C., Lam, Daisy, Chan, Michelle F. T.
Publicado 2016

Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with o...

por Poon, Darren M.C., Chan, Kuen, Lee, Siu H., Chan, Tim W., Sze, Henry, Lee, Eric K.C., Lam, Daisy, Chan, Michelle F.T.
Publicado 2018

Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer

por Poon, Darren M. C., Chan, Kuen, Chan, Tim, Cheung, Foo-Yiu, Lam, Daisy, Lam, Martin, Law, Ka-Suet, Lee, Conrad, Lee, Eric K. C., Leung, Angus, Sze, Henry, Tong, Chi-Chung, Wong, Kenneth C. W., Kwong, Philip
Publicado 2022